What's in Disc Medicine, Inc's pipeline?

Disc Medicine, Inc has 3 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 2 in Phase 2, 0 in Phase 1.

Which companies overlap with Disc Medicine, Inc's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/disc-medicine-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Disc Medicine, Inc — Portfolio Competitive Intelligence Brief

Disc Medicine, Inc pipeline: 0 marketed, 0 filed, 1 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
DISC-1459	DISC-1459	phase 3	Hepcidin mimetic	Ferroportin (iron exporter); hepcidin pathway agonist	Hematology

Therapeutic area mix

Hematology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Disc Medicine, Inc:

Cite this brief

Drug Landscape (2026). Disc Medicine, Inc — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/disc-medicine-inc. Accessed 2026-05-16.